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Pre-eclampsia disrupts the normal relationship
between serum leptin concentrations and adiposity
in pregnant women
Michelle A. Williamsa,c,f, Peter J. Havelb, Michael W.
Schwartzd,e, Wendy M. Leisenringh, Irena B. Kingg,
Rosalee W. Zingheima, Arthur M. Zebelmani and
David A. Luthya
aCenter for Perinatal Studies, Swedish Medical Center, Seattle, WA,
bDepartment of Nutrition, University of California, Davis, CA,
cDepartment of Epidemiology and dDivision of Metabolism, Endocri-
nology and Nutrition, Department of Medicine, University of
Washington, Seattle, WA, eVeterans Affairs Puget Sound Health Care
System, fProgram in Epidemiology, gDivision of Clinical Research,
hProgram in Biostatistics, Fred Hutchinson Cancer Research Center,
Seattle, WA, and iDynacare Laboratory of Pathology, Seattle, WA, USA
Summary. The adipocyte hormone, leptin, is secreted in proportion to
adipose mass and is implicated in the regulation of energy balance via its
central actions on food intake and sympathetic nervous system activity.
The placenta was also shown recently to be a possible source of leptin in
pregnant women, raising the possibility that the normal relationship
between leptin and adiposity may be altered in pre-eclampsia. We
therefore sought to assess the extent to which maternal second trimester
serum leptin concentrations differed for women who would subse-
quently develop pre-eclampsia and those who would remain normoten-
sive. This nested case±control study population comprised 38 women
with pregnancy-induced hypertension and proteinuria (pre-eclampsia)
and 192 normotensive women. Multiple least-squares regression proce-
dures were used to assess the independent relationship between leptin
concentrations and risk of pre-eclampsia. Serum leptin concentrations,
measured by radioimmunoassay, were highly correlated with maternal
pre-pregnancy and second trimester body mass index (r = 0.71 and
r = 0.74 respectively; P 5 0.001 for both) among normotensive women,
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and to a lesser extent among women who developed pre-eclampsia
(r = 0.29 and r = 0.42; P = 0.09 and 0.02 respectively). Among women with
a pre-pregnancy body mass index of 4 25 kg/m2, pre-eclampsia cases
compared with controls had higher mean second trimester leptin con-
centrations after adjustment for confounding factors. In contrast, pre-
eclampsia cases had lower mean leptin concentrations than controls for
those women with a pre-pregnancy body mass index above 25 kg/m2.
Other factors in addition to the level of adiposity may therefore influence
serum leptin concentrations in pre-eclamptic pregnant women. Our
results suggest the possibility that leptin, like several other placentally
derived substances (e.g. steroid hormones, eicosanoids and cytokines),
may be involved in the pathogenesis of pre-eclampsia. Further work is
needed to confirm our findings and to assess the metabolic importance
and determinants of leptin concentrations in uncomplicated and pre-
eclamptic pregnancies.
Introduction
Pre-eclampsia continues to be an important cause of maternal mortality as well as
perinatal morbidity and mortality worldwide.1 Although there is increasing
evidence that many of the symptoms of pre-eclampsia may be attributed to diffuse
endothelial dysfunction,2 the cause of this complex multisystem maternal disorder
remains unknown. Clinically, pre-eclampsia is characterised by maternal high
blood pressure, proteinuria and oedema. Women with the disorder also
experience profound, albeit transient, endocrine disturbances including hyperli-
pidaemia, particularly hypertriglyceridaemia,3,4 excessive lipid peroxidation or
oxidative stress,5,6 insulin resistance,3 sympathetic nervous system over-reactiv-
ity;7 plasma elevations of pro-inflammatory cytokines,8,9 elevations in the
placental hormone, human chorionic gonadotropin,10 and an imbalance in the
placental production and circulation of the eicosanoids, thromboxane and
prostacyclin.11,12 Poor utero-placental perfusion, secondary to incomplete en-
dovascular invasion by cytotrophoblasts is considered the primary aetiological
lesion of pre-eclampsia.2,13 Putative epidemiological risk factors for pre-eclampsia
include primiparity, young and advanced maternal age, and multiple pregnan-
cies.14,15 Increased maternal adiposity, as measured by high pre-pregnancy body
mass index, is also a strong and consistently identified risk factor for the
disorder,14±16 although little is known about the biological mechanisms under-
lying this epidemiological association.
Leptin, the product of the ob gene, is produced primarily by adipose tissue and
has been implicated in the regulation of energy balance via its central actions on
food intake and energy expenditure.17 In humans, circulating leptin concentrations
correlate with adiposity,18,19 and decrease after weight loss,19,20 fasting20 or caloric
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restriction.20 Recent studies, however, suggest that during pregnancy leptin is not
derived solely from the adipocyte. Maternal serum leptin concentrations have
been shown to increase during pregnancy to values greater than those predicted
for the degree of adiposity.21±23 Emerging evidence from in vivo and in vitro
studies indicate that the placenta, an important endocrine organ, is capable of
synthesising and secreting leptin into maternal and fetal circulation and may
contribute to pregnancy-associated elevations in circulating leptin concentrations.
Placentally derived leptin is also thought to be a source of leptin detected in
amniotic fluid, and arterial and venous cord blood.24
Given that pre-eclampsia is known to be associated with poor placental
endovascular invasion, diverse endocrine disturbances, and increased maternal
pre-pregnancy adiposity, and that leptin has been shown, by some,23 although not
all investigators,24 to be correlated with adiposity during pregnancy, we sought to
(1) assess the relationship between maternal second trimester serum leptin
concentrations in relation to maternal adiposity; and (2) assess maternal second
trimester serum leptin concentrations in women who remained normotensive
throughout pregnancy compared with women who developed pre-eclampsia.
Methods
A cohort of 1383 women providing a second trimester serum sample to a central
laboratory between December 1993 and August 1994, and who later delivered at
the Swedish Medical Center, constitute the base cohort study population wherein
the present case±control study is nested. Each blood sample, collected at 15±22
weeks' gestation, was centrifuged and serum was separated and stored at ±20 8C
after being subjected to routine biochemical analyses as part of a second trimester
screening protocol for detecting pregnancies complicated by neural tube defects
and Down's syndrome. Serum remaining after routine testing was transferred to
the Swedish Medical Center and stored at ±708C until analysis.
From this base cohort population of 1383 pregnant women, we identified 39
patients who subsequently developed pre-eclampsia, the diagnosis of which was
made in accordance with the guidelines of the American College of Obstetricians
and Gynecologists.25 Using serial maternal blood pressure readings and maternal
urinary protein results abstracted from medical records, pre-eclampsia was
defined as a sustained (6 or more hours) 15-mmHg diastolic rise or a 30-mmHg
rise in systolic blood pressure with proteinuria; if first trimester blood pressures
were unknown, a sustained (6 or more hours) blood pressure 5 140/90 mmHg
was used. Proteinuria was defined as urine protein concentration of 5 30 mg/dL
for two random specimens collected at least 4 h apart. Primiparity was not a
criterion for diagnosis for this investigation. In this base study population of 1383
primiparous and multiparous gravidas, the incidence of pre-eclampsia is
estimated at 2.8% (39/1383). Of the 39 pre-eclampsia cases, one subject had an
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inadequate amount of serum for leptin determination. Hence, 38 cases were
available for analysis.
Eligible controls were subjects who remained normotensive throughout
pregnancy. Owing to practical constraints, it was not possible to include all
normotensive pregnant women as controls. Therefore, using a stratified random
sampling algorithm, with stratification based on 3-month intervals within which
serum samples were collected, we identified 192 women to serve as controls.
Women with missing information for blood pressure and urinary protein test
results (n = 4) were not eligible for inclusion in this investigation, as a diagnosis of
pre-eclampsia could not be ruled out with certainty. Twenty-seven women with
pregnancy-induced hypertension without proteinuria (i.e. gestational hyperten-
sives) were not included in this study. Women with chronic hypertension
preceding the index pregnancy were not eligible for inclusion in this research. The
large number of controls provides approximately a 1:5 case to control ratio, thus
maximising statistical power.
Serum leptin concentrations were determined by radioimmunoassay26 with
reagents supplied by Linco Research, St Charles, MO, USA. The range of the
standard curve is 0.5±100 ng/mL. The intra- and interassay coefficients of
variation are 5 8%. The antibody used in the assay does not cross-react with
human insulin, proinsulin, glucagon, pancreatic polypeptide or somatostatin.
Information on maternal socio-demographic characteristics, reproductive and
medical histories, and labour and delivery characteristics, as well as anthropo-
metric measurements (maternal height, pre-pregnancy weight and weight at 18±
22 weeks' gestation) were abstracted from maternal medical records. Gestational
age was based on the last menstrual period and (when possible) confirmed by
ultrasound examination, conducted before 20 weeks' gestation. Body mass index,
used as a measure of maternal overall adiposity, was calculated as weight (in
kilograms) divided by height (in metres) squared. Maternal pregnancy weight
gain (up to 18±22 weeks' gestation) was calculated by subtracting maternal pre-
pregnancy weight from maternal weight measured at 18±22 weeks' gestation.
The distribution of maternal socio-demographic characteristics, medical and
reproductive histories according to case±control status was examined. The
distribution of continuous variables (e.g. serum leptin concentrations, body mass
index and maternal age) were checked and found to be approximately normal,
hence parametric statistical analytic procedures were used. Continuous variables
are presented as means+ standard deviation (SD). Unadjusted mean differences
in maternal serum leptin concentrations were assessed using Student's t-test
statistics. Comparisons of categorical variables were made between case and
control subjects using chi-squared or Fisher's Exact tests. In an effort to examine
the independent relationship between maternal serum leptin and pre-eclampsia
risk, we calculated the leptin:pre-pregnancy body mass index ratio as a means of
expressing individual leptin concentration per percentage body fat.19 A similar
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ratio was generated using maternal body mass index measured during the second
trimester (18±22 weeks' gestation). The Pearson's product±moment correlation
coefficient was used to measure the closeness of a linear relationship between
maternal second trimester leptin concentrations and selected characteristics
including maternal pre-pregnancy weight and pre-pregnancy body mass index.
Multiple linear least-squares regression analyses were conducted in order to
examine the independent relationship between maternal serum leptin concentra-
tions while controlling for potential confounding covariates such as maternal pre-
pregnancy body mass index, age, race, fetal gender and parity. Any covariate that
resulted in at least a 10% change in the coefficient for pre-eclampsia in the
regression model was considered a confounder and retained in the multivariate
model. For analyses which adjusted for maternal pre-pregnancy body mass index,
gestational age at blood collection was found to be a confounder and was
therefore included in the final regression model. Maternal race and fetal gender
were also found to be important confounders in analyses that considered maternal
second trimester body mass index. An interaction term between maternal
pre-pregnancy body mass index (and second trimester body mass index) and
a yes/no indicator variable, where `1' denotes case status and `0' denotes control
status, was also included in the model because univariate analyses indicated
that the relationship between leptin and maternal pre-pregnancy body mass
index varied according to pre-eclampsia outcome. The adjusted R2 value was
provided as a measure of the total variability in maternal serum leptin
concentrations explained by each model. Predicted leptin values were cal-
culated from final regression models along with 95% confidence intervals for the
predicted values.
Results
Socio-demographic, medical and reproductive characteristics of study subjects are
presented in Table 1. Women who developed pre-eclampsia compared with
control subjects tended to be heavier, primiparous and more likely to have a
positive family history of diabetes. Of note, cases and controls gained a similar
amount of weight by the second trimester. The average gestational age of blood
collection was similar for the two study groups (16.9+ 1.8 and 16.5+ 1.2 weeks'
gestation for cases and controls respectively). Among cases, maternal second
trimester serum leptin concentration ranged from 5.7 to 46.6 ng/mL, and was 21%
higher on average than for control subjects (20.2+ 1.5 vs. 16.7+ 0.7 ng/mL;
P = 0.040) (Table 1). Women who developed pre-eclampsia also had higher leptin
concentrations per unit pre-pregnancy body mass index than those women who
remained normotensive (0.85+ 0.06 vs. 0.71+ 0.03; P = 0.044). A similar case±
control difference was seen for leptin concentrations corrected for second trimester
body mass index.
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We next examined the association between maternal serum leptin concentra-
tion, pre-pregnancy and second trimester body mass index for women who
developed pre-eclampsia (cases). Analyses were repeated for those women who
remained normotensive throughout pregnancy (controls). Among control subjects,
second trimester leptin concentrations were positively correlated with maternal
pre-pregnancy weight (r = 0.64, P 5 0.0001), pre-pregnancy body mass index
(r = 0.71, P 5 0.0001) and second trimester body mass index (r = 0.74, P 5 0.0001).
Notably, correlation coefficients between second trimester serum leptin and
indices of maternal adiposity among pre-eclampsia cases were considerably lower
than those estimated for control subjects. Among pre-eclampsia cases, second
trimester leptin concentrations were weakly correlated with maternal pre-
pregnancy weight (r = 0.47, P 5 0.003), pre-pregnancy body mass index
(r = 0.42, P = 0.02) and second trimester body mass index (r = 0.29, P = 0.09).
Maternal serum leptin concentrations were not correlated with maternal weight
gain during pregnancy, gestational age at delivery or infant birthweight. Visual
inspection of regression lines estimated for pre-eclampsia cases and controls
indicated that the lines crossed at & 25 kg/m2.
Results from analyses stratified according to maternal adiposity indicated that
the relationship between plasma leptin concentrations and pre-eclampsia differed
for lean and obese women. Among women with a pre-pregnancy body mass index
4 25 kg/m2, serum leptin concentrations were 33% higher for cases than controls
(20.5+ 10.91 vs. 13.6+ 6.8 ng/mL; P = 0.005). For women with a pre-pregnancy
body mass index above 25 kg/m2, cases had leptin concentrations that were 20%
lower than those of controls (22.3+ 7.5 vs. 27.8+ 12.1 ng/mL; P = 0.084). The
results were similar when leptin was expressed per unit pre-pregnancy body mass
index. Among women with a pre-pregnancy body mass index 4 25 kg/m2, the
leptin:pre-pregnancy body mass ratio was 43% higher in pre-eclampsia cases than
in controls (0.91+ 0.45 vs. 0.63+ 0.30 ng/mL/kg/m2; P = 0.0013). In contrast,
the leptin per pre-pregnancy body mass index value was 18% lower for pre-
eclampsia cases than control subjects whose pre-pregnancy body mass index
exceeded 25 kg/m2 (0.79+ 0.26 vs. 0.96+ 0.39 ng/mL/kg/m2; P = 0.104).
We next sought to assess the association between second trimester leptin
concentrations and risk of pre-eclampsia after controlling for maternal pre-
pregnancy body mass index and other potential confounding factors. Estimated
coefficients and standard errors (SEs) for the covariates included in the final
regression model are presented in Table 2. Table 2 shows that the presence or
absence of pre-eclampsia is a major determinant of serum leptin concentrations
during the second trimester, even after adjusting for body mass index and other
confounding factors. The heterogeneity in association between maternal second
trimester leptin concentration and risk of pre-eclampsia according to maternal
adiposity is evident by the statistically significant interaction term in the model
(Table 2). Figure 1 shows the predicted values and 95% confidence intervals of
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serum leptin concentrations in relation to maternal pre-pregnancy body mass
index (i.e. predicted values from the model described in Table 2). The predicted
values of leptin are based on a model which allows for different slopes and
intercepts for cases and controls. Briefly, among women with a pre-pregnancy
body mass index of 4 25 kg/m2, pre-eclampsia cases had higher predicted second
trimester leptin concentrations than controls. For those women with a pre-
pregnancy body mass index above 25 kg/m2, pre-eclampsia cases had lower
predicted leptin concentrations than controls.
Table 2. Relationship between maternal serum leptin concentration in the second trimester
and pre-eclampsia (adjusted for pre-pregnancy body mass index)
Parameter Coefficient+ SE P
Pre-eclampsia 31.22+ 11.51 0.007
Pre-pregnancy body mass index 1.77+ 0.14 0.000
Pre-eclampsia 6 body mass index ±1.27+ 0.46 0.007
Gestational age at blood collection 0.27+ 0.45 0.543
Leptin expressed in ng/mL; body mass index in kg/m2.
Of the total variation in maternal second trimester leptin concentration, 44.9% (adjusted
R2 = 44.9%) is explained by this linear regression model.
Figure 1. Relationship of maternal second trimester serum leptin concentrations to pre-
pregnancy body mass index for pre-eclampsia cases (&) and normotensive control subjects
(*). The heavier line represents predicted serum leptin concentrations; the lighter line
represents pointwise 95% confidence intervals for predicted points Fitted values and
confidence intervals are from the least-squares regression model described in Table 2.
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Figure 2 shows the relationship between maternal second trimester body mass
index and leptin concentrations with pre-eclampsia, and Figure 3 shows the
relationship between pre-eclampsia status and maternal serum leptin per unit pre-
pregnancy body mass index. The corresponding results for the last two
multivariate models (Tables 3 and 4) are consistent with the observation that
the relationship between leptin and pre-eclampsia varies according to maternal
adiposity. Furthermore, as seen in Figure 3, the amount of leptin per unit body
mass index increases with maternal adiposity for women who remained
normotensive throughout pregnancy (circles). In contrast, among women who
developed pre-eclampsia (squares), the relationship between serum leptin
concentrations and maternal adiposity appears to be disrupted, as the amount
of leptin per unit body mass index is similar for lean and obese women. Results
from analyses which excluded two subjects with leptin values that were thought
to be outliers were not materially different from those reported here.
Discussion
We found that among both pre-eclamptic cases and normotensive controls,
maternal second trimester serum leptin concentrations were correlated with
maternal pre-pregnancy and second-trimester adiposity. Correlation coefficients
Figure 2. Relationship of maternal second trimester serum leptin concentrations to second
trimester body mass index for pre-eclampsia cases (&) and normotensive control subjects
(*). The heavier line represents predicted serum leptin concentrations; the lighter line
represents pointwise 95% confidence intervals for predicted points. Fitted values and
confidence intervals are from the least-squares regression model described in Table 3.
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between maternal adiposity and leptin concentrations among pre-eclampsia cases,
however, were considerably lower than those seen for control subjects. Since the
risk of pre-eclampsia and serum leptin concentrations both increase with
increasing adiposity, it was necessary to determine whether adiposity-adjusted
leptin concentrations were elevated in pre-eclampsia. After adjusting for possible
confounding by maternal body mass index, we noted that case±control differences
in leptin concentrations varied according to maternal adiposity. Specifically, lean
Figure 3. Relationship of maternal second trimester serum leptin concentrations (expressed
as per unit body mass index) to pre-pregnancy body mass index for pre-eclampsia cases
(&) and normotensive control subjects (*). The heavier line represents predicted serum
leptin concentrations; the lighter line represents pointwise 95% confidence intervals for
predicted points. Fitted values and confidence intervals are from the least-squares
regression model described in Table 4.
Table 3. Relationship between maternal serum leptin concentration in the second trimester
and pre-eclampsia (adjusted for second trimester body mass index)
Parameter Coefficient+ SE P
Pre-eclampsia 15.28+ 10.27 0.139
Second trimester body mass index 1.78+ 0.13 0.000
Pre-eclampsia 6 body mass index ±0.56+ 0.37 0.133
Maternal race (black/non-black) 4.26+ 2.18 0.052
Infant gender (male/female) 1.81+ 1.01 0.075
Leptin expressed in ng/mL; Body mass index in kg/m2.
Of the total variation in maternal second trimester leptin concentration, 52.5% (adjusted
R2 = 52.5%) is explained by this linear regression model.
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women who became pre-eclamptic had elevated leptin concentrations, whereas
the reverse was true for obese women who developed this condition.
Maternal second trimester serum leptin concentrations among control subjects
in our study are considerably lower than the 20±43 ng/mL reported among
unselected pregnant women at term by Schubring et al.22 and Butte et al.,23 which
may reflect the relatively low pre-pregnancy body mass index of our control
group (22.8+ 4.1 kg/m2). Our observation of a strong, statistically significant
correlation between maternal second trimester serum leptin concentrations and
pre-pregnancy body mass index, however, is in general agreement with results
reported for non-pregnant women.19,20 While our results are at variance with
those of Schubring et al.,22 who reported that there was no correlation between
maternal leptin concentrations (measured at term) with pre-pregnancy body mass
index, Hartman et al.27 in a study of 76 women with uncomplicated pregnancies
reported that maternal leptin concentrations and body mass index were correlated
(r = 0.47). These different outcomes may reflect differences in the timing of
maternal blood sampling, pre-pregnancy body mass index and presence or
absence of complications such as pre-eclampsia, each of which influence the
association between leptin concentrations and adiposity in pregnant women.
We are aware of only one published account of maternal leptin concentrations
in pre-eclamptic and normotensive pregnant women. In a cross-sectional case±
control study of 27 women with pre-eclampsia and an equal number of controls
matched for gestational age at delivery and maternal body mass index, McCarthy
et al.28 reported that maternal serum leptin levels at delivery were 28% higher
among cases than controls (43.23+ 19.9 vs. 33.68+ 18.4 ng/mL). These results are
in agreement with our findings, although results from our study extend these
findings by demonstrating that the relationship between maternal serum
concentrations and pre-eclampsia risk may vary by maternal pre-pregnancy
adiposity. Moreover, because we used a nested case±control study design where
leptin concentrations were determined using serum collected at 17 weeks'
gestation on average, we are able to show that the metabolic dysregulation of
serum leptin concentrations precedes the clinical manifestation of pre-eclampsia.
Table 4. Relationship between maternal serum leptin concentration (expressed as per unit
pre-pregnancy body mass index) in the second trimester and pre-eclampsia
Parameter Coefficient+ SE P
Pre-eclampsia 1.13+ 0.38 0.003
Pre-pregnancy body mass index 0.04+ 0.01 0.000
Pre-eclampsia 6 body mass index ±0.04+ 0.01 0.004
Leptin expressed in ng/mL per body mass index (kg/m2).
Of the total variation in maternal second trimester leptin:pre-pregnancy body mass index
ratio, 18.8% (adjusted R2 = 18.8%) is explained by this linear regression model.
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Several limitations must be considered when interpreting the results of our
study. First, inference from this investigation is hampered, in part, by the
relatively small number of cases studied. Without a larger number of pre-
eclampsia cases, we cannot thoroughly explore the apparent heterogeneity in the
association between leptin concentrations and pre-eclampsia according to
maternal adiposity. Second, we cannot completely exclude the possibility that
our results are unduly influenced by a few subjects who are not representative of
the larger population. Because of this concern, we repeated analyses after
excluding two cases with high body mass index and low leptin values and did not
observe differences that altered our conclusions.
Although the processes that control the synthesis and secretion of leptin in
maternal and fetal circulation during pregnancy are incompletely understood, two
independent reports indicate that the placenta is an important source of leptin in
human pregnancies. Indirect immunofluorescence analyses of first and third
trimester placental tissue revealed strong staining for immunoreactive leptin in
first trimester chorionic villi and third trimester syncytiotrophoblasts respec-
tively.21 These results are in agreement with those of Senaris and colleagues,24
who demonstrated that leptin is synthesised in syncytiotrophoblast cells harvested
from delivered placentas. Studies involving animal models also demonstrate a 2.7-
fold increase in uterine leptin receptor mRNA levels concurrent with a 1.8-fold
increase in leptin concentration during gestation.29 Thus, the pregnant uterus
probably makes a significant contribution to leptin levels in maternal blood.
This observation may help explain why the correlation coefficient between
leptin concentrations and adiposity among women who developed pre-eclampsia
was substantially lower than that observed among women who remained
normotensive throughout pregnancy (r = 0.42 vs. r = 0.71). We hypothesise that, in
addition to adipose mass, the placenta synthesizes and secretes leptin, and that
placentally derived leptin is affected by pre-eclampsia. Thus, pathological
placental changes associated with pre-eclampsia are hypothesised to modify the
relationship between maternal adiposity and leptin concentrations that is seen
among normotensive pregnant women. Although speculative, a scenario in which
pre-eclampsia among lean women is associated with increased placental leptin
secretion is consistent with our results. Studies to evaluate the expression of leptin
mRNA in placental tissue of pre-eclamptic and normotensive pregnant women of
variable adiposity are needed to evaluate this hypothesis.
The finding that leptin is associated with generalised sympathoactivation in
humans30 and rats31 suggests a possible physiological mechanism for our
observed association of leptin with pre-eclampsia risk among lean women. In a
study of 37 healthy men, basal muscle sympathetic nerve activity, a measure of
sympathetic nervous outflow, has been shown to be correlated with plasma leptin
concentrations (r = 0.44; P 5 0.01). In a rat model, it was shown that small
increases in plasma leptin concentrations, if sustained, produced a two- to
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threefold increase in sympathetic nerve activity in several tissues.31 One may
therefore consider the possibility that pregnancy-associated hyperleptinaemia in
lean women may increase the risk of sympathoactivation. Heightened sympa-
thetic nervous activity has been shown in pre-eclamptic compared with
normotensive pregnant women.7 In a study of nine pre-eclampsia cases and eight
normotensive pregnant controls, Schodel and colleagues7 reported that sympa-
thetic nerve activity (measured as bursts per 100 heart beats) were over threefold
higher in pre-eclamptic women than in controls. Based on these observations, one
must consider the possibility that the increased vascular resistance seen in pre-
eclampsia is mediated, in part, by factors capable of enhancing sympathoactiva-
tion. Results from at least two studies30,31 raise the possibility that leptin may be
one such mediator of sympathoactivation, although leptin has not been shown to
cause hypertension in studies to date. Firm conclusions therefore cannot be drawn
until direct study of the effect of leptin on sympathetic nervous system activity
and cardiovascular regulation is performed in animal models during pregnancy.
In summary, after adjusting for possible confounding factors, we noted that
case±control differences in leptin concentrations varied according to maternal
adiposity. Further work is needed to provide a better understanding of the
metabolic dysregulation of serum leptin concentrations in pre-eclampsia.
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